ViewRay, Inc. has announced highlights from ESTRO 36 held May 5-9 in Vienna, the annual meeting of the European Society for Radiotherapy and Oncology, which featured broad clinical experience with the company’s MRIdian System, including compelling early data on its use in pancreatic cancer.
A presentation by Sasa Mutic, Ph.D., from Washington University School of Medicine in St. Louis, highlighted early retrospective multi-institutional data on pancreatic cancer treatments with MRIdian at University of California, Los Angeles (UCLA) Health System; University of Wisconsin Carbone Cancer Center; VU University Medical Center; and Washington University School of Medicine. The study compared SBRT treatments with and without on-table adaptive dose reshaping and found that delivering a higher biological dose, enabled by MRI-guided on-table adaptive radiotherapy, may lead to improved survival in locally advanced pancreatic cancer.
A second clinical presentation on pancreatic cancer treatment with MRIdian was given by Anna Bruynzeel, M.D., Ph.D., from VU University Medical Center, focusing on their single-institutional experience. Early results illustrated MRIdian’s ability to deliver high doses with low toxicity, despite the proximity of the duodenum, through the use of daily plan adaptation and real-time tracking.
Following the promising data presented at ESTRO, ViewRay plans to support a multi-institutional single-arm prospective clinical trial in unresectable pancreatic cancer to demonstrate the benefits of MRIdian’s daily on-table adaptive SBRT and real-time tissue tracking capabilities, with a focus on toxicity, local control and overall survival outcomes.
In a talk in ViewRay’s booth, Frank Lagerwaard, M.D. Ph.D. of VU University Medical Center highlighted the excellent image quality of MRIdian and reported that on-table adaptation takes an average of less than fifteen minutes. Dr. Lagerwaard discussed the benefits of on-table adaptive treatments in a variety of cancers including pancreas, liver, kidney, lung, and prostate.
“We decided, from the very beginning, to leverage the benefits of MR guidance and MRIdian‘s integrated workflow to perform daily on-table adaptive treatments while using real-time MR tracking for every fraction,” said Dr. Lagerwaard. “With MRI-guidance and the ability to shape the dose on-table, we’re personalizing each treatment to ensure that the highest biologically effective dose is reaching the tumor and nearby healthy tissue and critical organs are spared, in an effort to improve patient outcomes. In our experience, this approach shows great promise, particularly in the treatment of pancreatic cancer.”
At a symposium titled “MRI-Guided RT with MRIdian: Perspectives from Installation to Clinical Use”, more than 400 attendees heard about the clinical experience at the first two European MRIdian centers, Gemelli ART in Rome and VU University Medical Center in Amsterdam, who are using on-table adaptive treatments on a daily basis.
Video highlights of select MRIdian presentations at ESTRO are available on ViewRay’s website at http://www.viewray.com/estro_2017.htm.Back To Top
ViewRay presents promising data on pancreatic cancer treatment with MRIdian. Appl Rad Oncol.